University of Leipzig Medical Center

The University of Leipzig Medical Center is a maximum care hospital which offers a wide spectrum of medical care.

Every year, around 400,000 people from Germany and abroad entrust their health to the University of Leipzig Medical Center. The hospital's employees, including doctors, nurses, administrative personnel, and staff employed by external contractors, work together to help patients regain their health and well-being.

Over 6,000 employees work in patient care, research and teaching for Leipzig University Medicine (UML).

Providing excellent, high-quality medicine, University of Leipzig Medical Center is one of the just two maximum care hospitals in Saxony. The University of Leipzig Medical Center enjoys one of the Europe's most advanced structural and technical infrastructures.

Therakos partners with the University of Leipzig Medical Center to strive toward the highest professional education standards and advance the knowledge on ECP technology. At the University of Leipzig Medical Center, a Center of Excellence is being held to provide accessible education to HCPs. Expert Key Opinion Leaders make up the Faculty:

Prof. Ziemer, Director of Extracorporeal Photopheresis, University of Leipzig Medical Center, Department of Dermatology, Allergology and Venereology
Prof. Simon, Clinical Director, University of Leipzig Medical Center, Department of Dermatology, Allergology and Venereology

Upcoming Courses

Mar 12 - 13, 2025

The Benefits of CELLEX™ Technology - Advancing Knowledge on ECP Technology

University of Leipzig Medical Center, Leipzig, Germany

Find out more

Sep 24 - 25, 2025

The Benefits of CELLEX™ Technology - Advancing Knowledge on ECP Technology

University of Leipzig Medical Center, Leipzig, Germany

Find out more

Faculty

Prof. Mirjana Ziemer

Prof. Ziemer activity is focused on Dermato-Histopathology, Dermato-Oncology and Extracorporeal Photopheresis. Since 2018 she has been involved as expert and coordinator in guidelines groups, including a group working on ECP. In 2010 she is appointed as Head of Extracorporeal Photopheresis, and since 2022 she is Trainer of the Centre of Excellence for advancing knowledge on EPC technology in Leipzig. She is member of several clinical societies, like the German Dermatological Society (DDG), Working Group on Dermatological Histology (ADH) of the DDG, German Cancer Society (DKG) and Working Group Dermatological Oncology (ADO) of the DDG.

Prof. Jan C. Simon

Prof. Jan C. Simon‘s activity is focused on immunodermatology, dermato-oncology and allergology.

Since 2003 he is Professor and Chairman of the Department of Dermatology, Venerology and Allergology and Director of the Skin Cancer Center at Leipzig University Medical Center. He published over 340 scientific articles .

He is a member of over 20 national and international scientific societies including leadership positions such as the Senate of the German National Academy of Sciences Leopoldina and the Board of the European Academy of Dermatovenerology.

Explore related courses

Mar 12 - 13, 2025

The Benefits of CELLEX™ Technology - Advancing Knowledge on ECP Technology

University of Leipzig Medical Center, Leipzig, Germany

Find out more

Sep 24 - 25, 2025

The Benefits of CELLEX™ Technology - Advancing Knowledge on ECP Technology

University of Leipzig Medical Center, Leipzig, Germany

Find out more

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

Indications

The THERAKOS™ CELLEX™ Photopheresis System is indicated for patients older than 18 years of age for the administration of photopheresis in the following:

Cutaneous T Cell Lymphoma (CTCL)
Solid Organ Transplant Rejection (SOT) (heart, lung)

The THERAKOS™ CELLEX™ Photopheresis System is indicated in patients older than 3 years of age for the management of:

Acute and Chronic Graft versus Host Disease (aGvHD, cGvHD)

Contraindications

THERAKOS^TM Photopheresis is contraindicated in:

Patients possessing a specific history of a light sensitive disease
Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm³
Patients who have coagulation disorders or who have previously had a splenectomy

Warnings and Precautions

THERAKOS^TMPhotopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure.

Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
When prescribing and administering THERAKOS Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
Treatment frequency exceeding labelling recommendations may result in anaemia.
Venous access carries a small risk of infection and pain.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS

Consult the 8-methoxypsoralen (Methoxsalen (20 micrograms / mL)) professional leaflet or the oral 8-methoxypsoralen formulation package insert before prescribing or dispensing any medication.

Warnings and Precautions

Patients exhibiting multiple basal cell carcinomas or having a history of basal cell carcinoma should be diligently observed and treated.
Methoxsalen may cause fetal harm when given to a pregnant woman. Women undergoing photopheresis should be advised to avoid becoming pregnant.
Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents.
Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic.
Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window.

Refer to the package insert for methoxsalen sterile solution (20 micrograms / mL) or the oral 8-methoxypsoralen dosage formulation for a list of all warnings and precautions.

University of Leipzig Medical Center, Leipzig, Germany

Upcoming Courses

The Benefits of CELLEX™ Technology - Advancing Knowledge on ECP Technology

The Benefits of CELLEX™ Technology - Advancing Knowledge on ECP Technology

Faculty

Prof. Mirjana Ziemer

Prof. Jan C. Simon

Explore related courses

The Benefits of CELLEX™ Technology - Advancing Knowledge on ECP Technology

The Benefits of CELLEX™ Technology - Advancing Knowledge on ECP Technology

Welcome to the Home of ECP

You are leaving the Therakos.eu website.

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOSTM PHOTOPHERESIS

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS